2-(6-氯-2-吡啶基)-1-(4-甲氧基苯基)乙酮肟 | 437384-16-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-(6-氯-2-吡啶基)-1-(4-甲氧基苯基)乙酮肟
• 英文名称: 2-(6-chloro-2-pyridinyl)-1-(4-methoxyphenyl)ethanone oxime
• 英文别名: 2-(6-Chloro-2-pyridinyl)-1-(4-methoxyphenyl)ethanone oxime；N-[2-(6-chloropyridin-2-yl)-1-(4-methoxyphenyl)ethylidene]hydroxylamine
• CAS: 437384-16-2
• 化学式: C₁₄H₁₃ClN₂O₂
• 分子量: 276.722
• InChiKey: FHGQNCCDHOCKSP-UHFFFAOYSA-N

物化性质

• 沸点：
  448.6±45.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  54.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(6-氯-2-吡啶基)-1-(4-甲氧基苯基)乙酮肟 在 三氟化硼乙醚 、 三乙胺 、 三氟乙酸酐 作用下， 以 乙二醇二甲醚 、 甲苯 为溶剂， 反应 8.0h， 生成 1-[7-chloro-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl]ethanone
  参考文献：
  名称：

  Synthesis of novel substituted 2-phenylpyrazolopyridines with potent activity against herpesviruses

  摘要：

  Herpesviruses are a significant source of human disease; amongst these herpes simplex virus 1 (HSV-1) and HSV-2 are very prevalent and cause recurrent infections. We recently identified a pyrazolo[1,5-a]pyridine scaffold that showed promising activity against HSV-1 and HSV-2 in Vero cell antiviral assays. Here, we describe the synthesis and anti-herpetic activity of several 3-pyrimidinyl-2-phenylpyrazolo[1,5-a]pyridines with differing 2-phenyl substitution patterns. Approaches to rapidly access a number of analogs with different 2-phenyl substitution patterns are outlined. Several of the compounds described have comparable activity to acyclovir against HSV-1 and HSV-2. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.05.043
• 作为产物：
  描述：

  2-甲基-6-氯吡啶 在 sodium hydroxide 、 盐酸羟胺 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 生成 2-(6-氯-2-吡啶基)-1-(4-甲氧基苯基)乙酮肟
  参考文献：
  名称：

  Synthesis of novel substituted 2-phenylpyrazolopyridines with potent activity against herpesviruses

  摘要：

  Herpesviruses are a significant source of human disease; amongst these herpes simplex virus 1 (HSV-1) and HSV-2 are very prevalent and cause recurrent infections. We recently identified a pyrazolo[1,5-a]pyridine scaffold that showed promising activity against HSV-1 and HSV-2 in Vero cell antiviral assays. Here, we describe the synthesis and anti-herpetic activity of several 3-pyrimidinyl-2-phenylpyrazolo[1,5-a]pyridines with differing 2-phenyl substitution patterns. Approaches to rapidly access a number of analogs with different 2-phenyl substitution patterns are outlined. Several of the compounds described have comparable activity to acyclovir against HSV-1 and HSV-2. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.05.043

文献信息

• Therapeutic compounds
  申请人：——

  公开号：US20040072853A1

  公开（公告）日：2004-04-15

  The present invention provides compounds of formula (I): wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents. 1

  本发明提供式(I)的化合物：其中所有变量如本文所定义，包含它们的药物组合物、制备它们的过程以及它们作为药物剂的用途。1
• Pyrazolopyridinyl pyrimidine therapeutic compounds
  申请人：SmithKline Beecham Corporation

  公开号：US07153855B2

  公开（公告）日：2006-12-26

  The present invention provides compounds of formula (I): pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

  本发明提供了公式(I)的化合物：包含它们的药物组合物，制备它们的方法以及它们作为药物剂的应用。
• Therapeutic Compounds
  申请人：Boyd Leslie F.

  公开号：US20060293344A1

  公开（公告）日：2006-12-28

  The present invention provides compounds of formula (I); pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

  本发明提供了式(I)的化合物；包含相同化合物的药物组合物，制备相同化合物的方法以及它们作为药物剂量的使用。
• Pyrazolopyridinyl pyridine and pyrimidine therapeutic compounds
  申请人：Chamberlain Stanley D.

  公开号：US06919352B2

  公开（公告）日：2005-07-19

  The present invention provides compounds of formula (I): wherein all variables are as defined herein, pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents.

  本发明提供了式(I)的化合物：其中所有变量均如本文所定义，含有其的制药组合物，制备该化合物的方法以及它们作为制药剂的用途。